Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Mastropasqua, Rodolfo ^a   Toto, Lisa ^b   Borrelli, Enrico ^b   Di Antonio, Luca ^b   De Nicola, Chiara ^b   Mastrocola, Alessandra ^b   Di Nicola, Marta ^b   Carpineto, Paolo ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ELECTRORETINOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MICROPERIMETRY; MULTIFOCAL ELECTRORETINOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATTERN ELECTRORETINOGRAPHY; PERIMETRY; PROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; ADMINISTRATION AND DOSAGE; AGED; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

AGED; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; TIME FACTORS;

EID: 84957055191     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145663     Document Type: Article

References (27)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol; 54:1-32. doi: 10.1016/j.survophthal.2008.10.001 PMID: 19171208
2. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of Vitreous Inflammatory Factors with Diabetic Macular Edema. Ophthalmology 2009;116:73-79. doi: 10.1016/j.ophtha.2008.09.037 PMID: 19118698
3. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999;96:10836-41. PMID: 10485912
4. Zitkus BS. Update on the American Diabetes Association Standards of Medical Care. Nurse Pract 2014;39:22-32.
5. Pacella E, La Torre G, Impallara D, Malarska K, Turchetti P, Brillante C, et al. Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up. Clin Ter 2013;164:e121-6. doi: 10.7417/CT.2013.1543 PMID: 23698213
6. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for Diabetic Macular Edema. Ophthalmology 2012;119:789-801. doi: 10.1016/j.ophtha.2011.12.039 PMID: 22330964
7. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology 2013;120:2013-2022. doi: 10.1016/j.ophtha.2013.02.034 PMID: 23706949
8. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14. doi: 10.1016/j.ophtha.2014.04.024 PMID: 24907062
9. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541-6. PMID: 18670086
10. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4. PMID: 15790913
11. Bandello F, Lattanzio R, Zarbin MA, Zucchiatti I. Clinical Strategies in the Management of Diabetic Retinopathy: A Step-by-Step Guide for Ophthalmologists. 1st ed. Springer-Verlag Berlin Heidelberg; 2014.
12. Haller JA. Randomized Controlled Trial of an Intravitreous Dexamethasone Drug Delivery System in Patients With Diabetic Macular Edema. Arch Ophthalmol 2010;128:289. doi: 10.1001/archophthalmol. 2010.21 PMID: 20212197
13. Bandello F, Battaglia Parodi M, Tremolada G, Lattanzio R, De Benedetto U, Iacono P. Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 2010;224 Suppl: 41-5.
14. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex1) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423-8. doi: 10.2147/OPTH. S48364 PMID: 23901252
15. Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 2012;124:1-13.
16. Bach M, Brigell MG, Hawlina M, Holder GE, Johnson MA, McCulloch DL, et al. ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 2012;126:1-7. doi: 10.1007/s10633-012-9353-y PMID: 23073702
17. Pacella E, La Torre G, Turchetti P, Merisola C, Lenzi T, Mazzeo F, et al. Evaluation of efficacy dexamethasone intravitreal implant compared to treatment with anti-VEGF in the treatment of diabetic macular edema. Senses Sci 2014;1(4):164-168.
18. De Benedetto U, Querques G, Lattanzio R, Borrelli E, Triolo G, Maestranzi G, et al. Macular dysfunction is common in both type 1 and type 2 diabetic patients without macular edema. Retina 2014;34:2171-7. doi: 10.1097/IAE.0000000000000205 PMID: 24978668
19. Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006;47:3044-51. PMID: 16799051
20. Bearse MA, Ozawa GY. Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema. Curr Diab Rep. 2014;14:526. doi: 10.1007/s11892-014-0526-9 PMID: 25005120
21. Querques G, Cascavilla ML, Cavallero E, Triolo G, Querques L, Lattanzio R, et al. Changes in macular function after ozurdex for retinal vein occlusion. Optom Vis Sci 2014;91:760-8. doi: 10.1097/OPX. 0000000000000308 PMID: 24927143
22. Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, et al. Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Retina 2014;34:330-41. doi: 10.1097/IAE.0b013e31829f7495 PMID: 23945638
23. Simó R, Hernández C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 2014;25:23-33. doi: 10.1016/j.tem.2013.09.005 PMID: 24183659
24. Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr Med Chem 2013;20:3241-50. PMID: 23745549
25. Dong N, Xu B, Chu L, Tang X. Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema. PLoS One 2015;10:e0125329. doi: 10.1371/journal.pone.0125329 PMID: 25923230
26. Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ, et al. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 2011;52:1336-44. doi: 10.1167/iovs.10-5768 PMID: 21212173
27. Scaramuzzi M, Querques G, Spina C La Lattanzio R, Bandello F. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015;35:1216-22. doi: 10.1097/IAE. 0000000000000443 PMID: 25574787